Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line
Seattle Genetics and their partners at Astellas and Merck continue to build a case for quickly expanding the market reach of their trendsetting antibody drug conjugate enfortumab vedotin. Four months after they rolled into ESMO with solidly positive data in the frontline setting for bladder cancer — and just ahead of the Nectin-4 targeted drug’s accelerated approval at the FDA for second-line cases — investigators are back with an update that supports their case on durability and efficacy in a frontline niche.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.